Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 328

Sort by

Sort Order Select

Journal Articles

Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum

Juthakorn Poothong, Anita Pottekat, Marina Siirin, Alexandre Rosa Campos, Adrienne W. Paton, James C. Paton, Jacqueline Lagunas-Acosta, Zhouji Chen, Mark Swift, Niels Volkmann, Dorit Hanein, Jing Yong, Randal J. Kaufman

Blood (2020) 135 (21): 1899–1911.

https://doi.org/10.1182/blood.2019002867

Published: 2020

Includes: Supplemental data

Journal Articles

Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases

Sæmundur Rögnvaldsson, MD, Ingemar Turesson, MD PhD, Magnus Björkholm, MD PhD, Ola Landgren, MD PhD, Sigurður Yngvi Kristinsson, MD PhD

Blood (2019) 134 (Supplement_1): 5444.

https://doi.org/10.1182/blood-2019-131514

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

Role of MMP-13 in Graft-Versus-Host Disease

Hui-Hui Ma, PhD, Jing Fu, PhD, Suzanne Lentzsch, MD PhD, Markus Y Mapara, MD PhD

Blood (2019) 134 (Supplement_1): 1928.

https://doi.org/10.1182/blood-2019-127703

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, Chen Yang, Lewis M Brown, PhD, Stephen J Weiss, MD PhD, Charles G Drake, MD PhD, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3072.

https://doi.org/10.1182/blood-2019-129177

Published: 2019

Journal Articles

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Susanne Beck, Martina Emde, Jerome Moreaux, PhD, Anja Seckinger, Dirk Hose, MD

Blood (2019) 134 (Supplement_1): 3078.

https://doi.org/10.1182/blood-2019-131161

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3165.

https://doi.org/10.1182/blood-2019-124370

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Divaya Bhutani, MD, Siyang Leng, MD, Samuel Pan, Amer Assal, MD, Alexander Wei, Julia Gould, BA, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3196.

https://doi.org/10.1182/blood-2019-130207

Published: 2019

Journal Articles

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Georg Jeryczynski, MD, Antonia Eder, Eva-Maria Reitter, MD, Maria-Theresa Krauth, MD, Hermine Agis, MD

Blood (2019) 134 (Supplement_1): 3123.

https://doi.org/10.1182/blood-2019-124681

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Blood (2019) 134 (Supplement_1): 3157.

https://doi.org/10.1182/blood-2019-122902

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Detailed Functional Characterization of Splenic Marginal Zone Lymphoma: Uncovering Links between the Epigenetic and the Signaling Machinery

Stavroula Ntoufa, Maria Gounari, Nikos Papakonstantinou, Despoina Binou, Ioannis Tyritidis, Theodora Stivarou, Ioannis Sarrigeorgiou, Anastasia Iatrou, Niki Stavroyianni, Achilles Anagnostopoulos, Peggy Lymberi, Kostas Stamatopoulos

Blood (2019) 134 (Supplement_1): 1512.

https://doi.org/10.1182/blood-2019-127909

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum

Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases

The UK Experience of Renal Transplantation in AL Amyloidosis

Role of MMP-13 in Graft-Versus-Host Disease

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Detailed Functional Characterization of Splenic Marginal Zone Lymphoma: Uncovering Links between the Epigenetic and the Signaling Machinery

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only